Allurion's Innovative Approach to Optimize Muscle Mass During GLP-1 Therapy

Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, has announced plans to optimize muscle mass during GLP-1 therapy in combination with the Allurion Program. This innovative approach aims to address the unmet need of muscle mass retention in patients undergoing GLP-1 therapy, which has been shown to result in significant muscle mass loss (up to 40% of total weight lost) in previous studies.



The Allurion Program combines the Allurion Gastric Balloon, the world's first and only swallowable, procedure-less gastric balloon for weight loss, with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Gastric Balloon is an investigational device in the United States.

In previous studies, patients treated with the Allurion Balloon in combination with the Allurion Virtual Care Suite have demonstrated strong patient outcomes in which patients lose weight while maintaining, and in some cases, increasing, muscle mass. In one study of 571 patients, patients treated with the Allurion Balloon gained 5.6% in lean body mass while losing 14% of their total body weight over four months. In another study of 167 patients, patients treated with the Allurion Balloon experienced a weight reduction of 15.7% with no change in muscle mass.



The proposed clinical study by Allurion aims to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can lose significant weight while increasing muscle mass and improving overall body composition. If successful, this combination could become a significant addition to the possibilities of GLP-1 therapies and potentially the gold standard for obesity care.

Dr. Shantanu Gaur, Founder and CEO of Allurion, stated, "Reductions in lean mass and muscle wasting are significant unmet needs in the GLP-1 space, and our early data suggests that we may have a powerful tool in achieving more metabolically healthy weight loss. The goal of our study would be to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can lose significant weight while increasing muscle mass and improving overall body composition. We are optimistic that this would be a significant addition to the possibilities of GLP-1 therapies and, if proven, could become the gold standard for obesity care."

In conclusion, Allurion's innovative approach to optimizing muscle mass during GLP-1 therapy in combination with the Allurion Program holds great promise for patients seeking to lose weight while maintaining and even increasing muscle mass. The proposed clinical study aims to validate this approach and establish a new standard for obesity care. As the study progresses, investors and healthcare providers alike will be watching closely to see if Allurion's innovative solution can deliver on its potential.